HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Mwaikambo, B. R. Articles by Hardy, P. Search for Related Content PubMed PubMed Citation Articles by Mwaikambo, B. R. Articles by Hardy, P.

Activation of CD36 Inhibits and Induces Regression of Inflammatory Corneal Neovascularization

¹From the Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada; the ²Departments of Paediatrics, Ophthalmology, and Pharmacology, Research Center, Ste. Justine Hospital, Université de Montréal, Montreal, Québec, Canada; ³INSERM U. 598 Physiopathologie des Maladies Oculaires: Innovations Thérapeutiques, Paris, France; and the ⁴Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada.

PURPOSE. This study was undertaken to investigate the role of the antiangiogenic receptor CD36 during inflammatory corneal neovascularization (CNV).

METHODS. In a murine model of inflammatory CNV, CD36 expression was evaluated by RT-PCR and immunofluorescence. Mice subjected to CNV were treated topically (thrice daily) with CD36 functionally neutralizing antibodies against the oxidized low-density lipoprotein (oxLDL) and thrombospondin (TSP)-1 sites (clones JC63.1 and FA6-152, respectively). Neovascularization was analyzed by CD31-immunostained corneal flatmounts. The role of the less characterized oxLDL site during angiogenesis was elucidated by using the CD36 ligand 1-palmitoyl 2-(5'-oxovaleroyl) phosphatidylcholine (POVPC; 50, 100 µg/mL) 24 hours after corneal injury for 7 days, whereas in angioregressive studies, POVPC treatments were initiated 10 days after induction of CNV. In this process, VEGF expression was also studied. Effects of CD36 activation were further examined ex vivo using the mouse aortic ring assay.

RESULTS. CD36 expression was upregulated after corneal injury; CD36 was expressed in corneal epithelium, limbus, invading microvessels, and stromal macrophages. Blocking CD36 activity with FA6-152 significantly increased CNV (P <0.001). Conversely, activating CD36 with POVPC dose dependently inhibited CNV (P = 0.003); this effect was blocked by JC61.3. POVPC also significantly regressed preformed blood vessels (P < 0.001). Ex vivo experiments on aortic rings confirmed the angioinhibitory and -regressive effects of POVPC. Because corneal macrophages express CD36 and may partake in angiogenesis via VEGF-A secretion, we surmised that VEGF-A could be modulated by CD36. Indeed, POVPC downregulated VEGF-A expression in a time-dependent fashion (P < 0.001), whereas FA6-152 induced its expression (P < 0.05).

CONCLUSIONS. CD36 is involved both physiologically and pharmacologically in inhibition and regression of CNV, by direct effect on endothelial cells and partly by negatively regulating VEGF expression in macrophages.

This article has been cited by other articles:

				L. Wang, J. Gao, W. Dai, and L. Lu Activation of Polo-like Kinase 3 by Hypoxic Stresses J. Biol. Chem., September 19, 2008; 283(38): 25928 - 25935. [Abstract] [Full Text] [PDF]

				A. Seth, J. Cui, E. To, M. Kwee, and J. Matsubara Complement-Associated Deposits in the Human Retina Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 743 - 750. [Abstract] [Full Text] [PDF]

				C. Yang, B. R. Mwaikambo, T. Zhu, C. Gagnon, J. Lafleur, S. Seshadri, P. Lachapelle, J.-C. Lavoie, S. Chemtob, and P. Hardy Lymphocytic microparticles inhibit angiogenesis by stimulating oxidative stress and negatively regulating VEGF-induced pathways Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R467 - R476. [Abstract] [Full Text] [PDF]

				S. Collot-Teixeira, J. Martin, C. McDermott-Roe, R. Poston, and J. L. McGregor CD36 and macrophages in atherosclerosis Cardiovasc Res, August 1, 2007; 75(3): 468 - 477. [Abstract] [Full Text] [PDF]